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OPEN ACCESSiScienceArticleCirculating argonaute-bound microRNA-126 reports
vascular dysfunction and treatment response
in acute and chronic kidney disease
Kathleen M. Scullion,1 A. D. Bastiaan Vliegenthart,1 Laura Rivoli,1 Wilna Oosthuyzen,1 Tariq E. Farrah,1
Alicja Czopek,1 David J. Webb,1 Robert W. Hunter,1 Matthew A. Bailey,1 Neeraj Dhaun,1,2
and James W. Dear1,2,3,*SUMMARY
Vascular and kidney dysfunction commonly co-exist. There is a need for bio-
markers of vascular health. Circulating microRNAs are biomarkers; miR-126 is
endothelial cell-enriched. We measured circulating miR-126 in rats with nephro-
toxic nephritis (NTN) and humans with acute endothelial and renal injury (vascu-
litis associated with autoantibodies to neutrophil cytoplasm antigens (ANCAs)).
We compared these findings to those from patients with chronic kidney disease
(CKD) and end-stage renal disease (ESRD) and explored the relationship between
miR-126 and vascular dysfunction. In NTN, miR-126 was reduced. In ANCA vascu-
litis (N = 70), pre-treatment miR-126 was reduced compared to health (N = 60)
(88-fold). miR-126 increased 3.4-fold post-treatment but remained lower than
in health (26-fold). Argonaute 2-bound miR-126 increased with ANCA vasculitis
treatment. miR-126 did not differ between CKD (N = 30) and health but its con-
centration correlated with endothelial dysfunction. miR-126 was reduced in
ESRD (N = 15) (350 fold). miR-126 may be a marker of vascular inflammation
















Vascular dysfunction commonly co-exists with kidney disease and contributes to an increased risk of car-
diovascular disease (CVD). A severe, acute form of this vascular-renal phenotype is seen in patients pre-
senting with anti-neutrophil cytoplasm antibody-associated vasculitis (AAV), a rare autoimmune disorder.
The most frequent severe manifestations of AAV involve endothelial injury giving rise to a rapidly progres-
sive glomerulonephritis and pulmonary hemorrhage. Despite current treatments overall survival remains
poor (Flossmann et al., 2011; Hoffman et al., 1992) with many patients suffering chronic inflammation, a ma-
jor contributor to the development and progression of both CVD (Hahn, 2003) and chronic kidney disease
(CKD) (Landray et al., 2004). Furthermore, those who respond to treatment remain at risk of further disease
relapses (Boomsma et al., 2000).
Identifying AAV early and assessing its response to treatment remain important clinical challenges. In those
with renal involvement, the measurement of renal function using serum creatinine is often inadequate
because substantial renal damage can occur before function is impaired to a detectable extent (Hewitt
et al., 2004). Additionally, although serum creatinine may fall with treatment, it remains unclear whether his-
tological inflammation continues once renal function has stabilized. Also, currently, there are no goodmea-
sures of disease activity in those with extra-renal AAV alone. Biomarkers specific to small vessel inflamma-
tion would not only allow early implementation of appropriate treatments but also help identify those
patients with grumbling disease activity and potentially predict disease relapses (Kitching et al., 2020).
While AAV might be considered a phenotypic extreme, patients with CKD due to any cause are at an
increased risk of CVD (Foley et al., 1998). Indeed, those with CKD have a substantially higher chance of
dying from CVD than of progressing to end-stage renal disease (ESRD) (Sarnak et al., 2003). Increased arte-
rial stiffness, a marker of CVD risk (Blacher et al., 1999; Guerin et al., 2008), is a commonly recognized
feature of CKD (Guerin et al., 2008), and an independent predictor of mortality and survival in these patientsiScience 24, 101937, January 22, 2021 ª 2020 The Author(s).

















































Figure 1. Circulating miRs in rats with nephrotoxic nephritis (NTN) and controls
Each point represents the 2dct value (normalized by miR-1287) of circulating miR-126 (A), miR-122 (B) and miR-125a (C).




Article(Blacher et al., 1999; Guerin et al., 2001). The endothelium is an important regulator of arterial stiffness (Wil-
kinson et al., 2004), and endothelial dysfunction is also a common feature of CKD (Endemann and Schiffrin,
2004; van Guldener et al., 1997, 1998) and a predictor of CVD (Perticone et al., 2001).
MicroRNAs (miRs) are small (22 nucleotide-long) non-protein coding RNA species involved in post-tran-
scriptional gene product regulation (Bartel, 2009). In blood, miRs are reported to be stable being protected
from degradation by extra-cellular vesicles (such as exosomes), RNA binding protein complexes (such as
argonaute 2 – Ago2) and lipoproteins (Mitchell et al., 2008; Zhou et al., 2013). As miRs are amplifiable
and some are tissue restricted, they represent a new reservoir for biomarker discovery. For example,
miR-122 is an established biomarker for liver injury (Starkey Lewis et al., 2011).
miR-126 is enriched in endothelial cells and is a regulator of vascular integrity and angiogenesis. The -3p
and -5p forms of miR-126 have activity in endothelial cells – 3p is anti-inflammatory (Harris et al., 2008)
and 5p is pro-proliferative (Schober et al., 2014). miR-126 is reported to be released from endothelial cells
bound to Ago2 and in extra-cellular vesicles, which can transfer functional miR-126 into recipient cells to
promote vascular repair (Zhou et al., 2013). When endothelial cells were stimulated with the pro-inflamma-
tory cytokine TNFa, the miR-126 cargo of their extra-cellular vesicles was reduced by 80%, consistent with
vesicular miR-126 reporting endothelial inflammation (Alexy et al., 2014). Reduced levels of circulating miR-
126 have been described as a potential biomarker for vascular disorders such as diabetes (Jansen et al.,
2013; Zampetaki et al., 2010) and myocardial infarction (Zampetaki et al., 2012). In patients with CKD,
miR-126 has been reported to fall with worsening renal function (Fourdinier et al., 2019). miR-126 is also ex-
pressed in platelets (Kaudewitz et al., 2016) and its circulating level has been reported to reflect the circu-
lating platelet count and activation state (Lorenzen et al., 2012; Willeit et al., 2013).
We hypothesized that circulating miR-126 would report vascular dysfunction in patients with kidney dis-
ease. As ‘proof-of-concept’, we first measured miR-126 in a relevant animal model, then in those with
AAV. Finally, we measured miR-126 in patients with CKD and ESRD, as well as explored the relationship
with established measures of endothelial function.
RESULTS
Circulating miR in NTN model
In NTN rats, plasma miR-126 was reduced compared with untreated controls when the data were normal-
ized by miR-1287 (Figure 1). This reduction in miR-126 was also reported by raw Ct values without any
normalization (control Ct 27.6 [27.0–27.8], n = 6, NTN Ct 29.3 [28.4–30.1], n = 5, p = 0.02) There were no
differences in miR-122 or miR-125a-5p between NTN and controls (Figure 1).
Effect of blood processing
In healthy subjects, there was a significant difference in miR-126 concentration between plasma and serum.
There was a significant decrease in miR-126 after blood storage for 24hr at both room temperature and at
4C (Figure S1A). After 7d delay in processing, the concentration of miR-126 significantly increased relative
to 24hr. Hemolysis accompanied this increase in miR-126 (for serum, no delay: A414 0.22 [0.20–0.31]; 7d
delay: A414 1.80 [0.60–1.80], p = 0.03; for plasma, no delay: A414 0.16 [0.16–0.28]; 7d delay: A414 0.30
[0.22–0.45]; p = 0.03). Based on these data, only immediately processed plasma samples were used in all2 iScience 24, 101937, January 22, 2021
Table 1. Clinical data for patients with AAV pre- and post-treatment
Characteristics Pre-treatment (n = 70) Post-treatment (n = 70) p value
Age, years 62 G 14 (27–82) – –
Sex, M/F 43/27 – –
Organs involved 2 G 1 (1–6) – –
Kidney 44 – –
Lung 33 – –
ENT 17 – –
Nerve 13 – –
Eyes 9 – –
eGFR, mL/min/1.73m2 46 G 34 (4–124) 57 G 29 (9–121) 0.04
Creatinine, mmol/L 200 G 177 (54–962) 150 G 144 (64–1000) 0.03
ALT, U/L 20 G 15 (6–83) 20 G 10 (4–48) 0.94
ALP, U/L 96 G 62 (13–338) 67 G 18 (39–122) <0.001
GGT, U/L 55 G 44 (11–182) 33 G 26 (10–148) <0.001
Albumin, g/L 28 G 7 (14–41) 37 G 4 (24–46) <0.0001
CRP, mg/L 82 G 75 (3–275) 6 G 15 (0–108) <0.0001
Hemoglobin, g/L 107 G 23 (62–157) 124 G 28 (2–170) <0.0001
Urine protein:creatinine mg/mmol 141 G 188 (0–948) 107 G 146 (0–531) 0.82
The data are shown as mean G SD with range. Significance of numerical data between groups was ascertained using a 2-




Articlesubsequent studies. After processing human blood into plasma or serum, storage at room temperature or
4C for 24 hr or 7 days had no statistically significant effect on miR-126 concentration (Figure S1B). There-
fore, after immediate isolation of plasma from blood, samples could be stored for short periods before
analysis.
Circulating miR in AAV
Seventy patients with AAV were recruited into this study. Pre- and post-treatment clinical data are shown in
Table 1. No patients had diabetes or received anti-platelet treatment. Pre-treatment, the plasma miR-126
concentration was 88-fold lower than in healthy controls (AAV median 0.8 fM [IQR 0.3–2.9], healthy subjects
70.4 fM (17.2–770) (Figure 2). ROC analysis was performed to quantify the accuracy of miR-126 with regard
to distinguishing health from AAV. The area under the curve was 0.87 (95% CI: 0.80–0.94). At a cutoff of
>33fM, specificity was 96% (95% CI: 88–99) and sensitivity was 69% (57–80). Post-treatment, all 70 patients
achieved disease remission (Table 1). Plasma miR-126 concentration increased 3.4-fold from pre-treatment
levels (post-treatment median 2.7 fM [IQR 0.5–9.8]) but did not return to healthy levels. miR-122 plasma
concentrations were not different between pre- and post-treatment samples from patients with AAV
(pre-treatment 1.6 fM [0.7–3.4], post-treatment 1.8 fM [0.7–4.7]). There was no correlation between miR-
126 and the patient’s platelet count either pre- or post-treatment (Figure S2A).
Urine miR-126 was measured pre- and post-immunosuppressive treatment (Figure 3). Using 3 different
normalization methods (spike-in microRNA, urinary creatinine or internal microRNA) the urinary concentra-
tion of miR-126 consistently decreased post-treatment.
Mechanism of miR-126 release into the circulation
miRs circulate bound to proteins or encapsulated in extra-cellular vesicles such as exosomes. Plasma from
healthy volunteers was fractionated by differential centrifugation and extra-cellular vesicles were isolated
(confirmed by nanoparticle tracking analysis – Figure 4A). miR-126 was enriched in the ‘protein fraction’ as
opposed to the extra-cellular vesicle fraction (29-fold increase in supernatant compared to pellet) (Fig-
ure 4B). The RNA binding protein Ago2 was isolated from plasma and the bound miR-126 concentration
measured. There was a significant increase in Ago2-bound miR-126 in those with AAV post-treatmentiScience 24, 101937, January 22, 2021 3



































Figure 2. The concentration of miR-126 in patients with ANCA-associated vasculitis (AAV) (n = 70 paired) pre- and
post-treatment, healthy volunteers (n = 60), chronic kidney disease (CKD) (n = 30) and end-stage renal disease (n =
15 paired) pre- and post-hemodialysis (HD)





Article(Figure 4C), consistent with this miR biomarker being specifically bound to Ago2. By contrast there was no
significant treatment-induced change in miR-126 in the extra-cellular vesicle fraction (Figure 4D). There was
no increase in Ago2-bound miR-122 and no change in plasma Ago2 concentration with treatment (data not
shown).
Circulating miR-126 in CKD
Having demonstrated proof-of-concept that miR-126 changes with acute endothelial/kidney injury, we
explored its circulating concentration in CKD. This condition is associated with chronic endothelial dysfunc-
tion and high cardiovascular risk. There were no patients in this cohort with diabetes. Samples were
analyzed from patients with CKD (n = 30) and hemodialysis-dependent ESRD (n = 15), immediately before
and after dialysis (Table 2). In patients with ESRD, miR-126 was substantially reduced compared with
healthy subjects and patients with CKD (352- and 358-fold, respectively). There was a modest increase
following a hemodialysis session (4.7-fold) (Figure 2). There was a range of plasma miR concentrations in
patients with CKD, which we hypothesized might reflect differences in vascular health across this patient
group. For these patients, we correlated miR concentrations against a range of well-recognized measures
of vascular function. miR-126 correlated significantly with PWV (r2 = 0.2), circulating ADMA (r2 = 0.28), ET-1
(r2 = 0.14) and urate concentrations (r2 = 0.19), as well as proteinuria (r2 = 0.17) (Figure 5). miR-126 correlated
weakly with serum creatinine (r2 = 0.12). There was no relationship between miR-122 and any of the mea-
sures of vascular or renal function assessed. There was no correlation between miR-126 and the patient’s
platelet count either in the CKD or ESRD groups (Figures S2B and S2C).
DISCUSSION
The current study develops the potential role of miR-126 as a circulating biomarker of vascular function in
acute and CKD. We initially achieved proof of concept in rodents and then went on to study AAV as a pro-
totype of severe, acute kidney injury and vascular dysfunction that is aggressively treated with immunosup-
pression. Then, we went on to study patients with CKD as they have a heavy burden of vascular dysfunction.
In a clinically relevant rat model, a lower circulating miR-126 (but not other miR species) was associated with
disease. We have demonstrated that in patients with AAV, circulating miR-126 concentrations are low at
disease presentation and rise with successful treatment. Pre-treatment levels are lower than those seen
in health and in CKD. Following treatment, miR-126 rises but not to levels seen in health. A liver-specific
miR species (miR-122) showed no differences in patients with AAV before or after treatment. In patients
with CKD, miR-126 correlated with other markers of vascular health. miR-126 was substantially reduced
in patients with ESRD. Thus, miR-126 may be a useful marker of vascular inflammation and, with develop-
ment, may help clinical decision-making.4 iScience 24, 101937, January 22, 2021
A B C
Figure 3. Urine miR-126 in patients with AAV, pre- (Pre-AAV) and post- (Post-AAV) treatment
Each point represents the 2dct value (normalized by C.elegansmiR-39 spike-in control (A), urinary creatinine concentration (B) and miR-671 (C)) of miR-126.




ArticlemiRs are an area of substantial research interest, in part because they represent potential disease bio-
markers. It is widely believed that one of their key properties is that they are stable in the circulation (Mitch-
ell et al., 2008). In the current study, we have demonstrated that for miR-126 this is not the case: significant
degradation occurred if the sample was left unprocessed for 24hr. We have reported similar instability for
miR-122 (Lopez-Longarela et al., 2020). We also demonstrated that hemolysis may increase the concentra-
tion of miR-126 present in the sample. Furthermore, despite reports that miRs are detected at similar con-
centrations in plasma and serum, plasma miR-126 was substantially higher than serum. Therefore, we
recommend the immediate processing of plasma samples in future studies of miR-126.A B
C D
Figure 4. miR-126 is bound to argonaute 2 (Ago2) in human plasma
(A) size and number of particles measured by nanoparticle tracking analysis (NTA) following isolation of extra-cellular
vesicles from human plasma by differential centrifugation.
(B) Dot plot of miR-126 measured in the extra-cellular vesicle containing pellet and supernatant after ultracentrifugation
of human plasma.
(C) Dot plot of miR-126 measured in the antibody isolated Ago2 fraction from 8 patients with AAV before treatment (Pre-
AAV) and after treatment (Post-AAV). The y axis represents copy number obtained from the Ago2 pull-down minus the
copy number obtained from IgG control pull-down from the same sample.
(D) Dot plot of miR-126 measured in the extra-cellular vesicle containing pellet from 8 patients with AAV before treatment
(Pre-AAV) and after treatment (Post-AAV). The horizontal line represents the median and the error bars represent the IQR.
Significance determined by Wilcoxon Test.
iScience 24, 101937, January 22, 2021 5
Table 2. Clinical data obtained for CKD patients and ESRD patients pre-hemodialysis (HD)
Characteristics CKD (n = 30) Pre-HD (n = 15)
Age, years 56 G 16 (26–82) 59 G 12 (34–82)
Sex, M/F 21/9 8/7
eGFR, mL/min/1.73m2 25 G 14 (7–57) –
Creatinine, mmol/L 217 G 133 (76–654) –
ALT, U/L 19 G 8 (9–50) 15 G 6 (7–25)
ALP, U/L 97 G 38 (40–182) 100 G 43 (52–178)
CRP, mg/L 5 G 2 (2–7) 14 G 21 (2–77)
Hemoglobin, g/L 123 G 16 (83–160) 122 G 12.51 (94–139)




ArticlemiR-126 increased in the circulation following successful treatment of patients with AAV. There was no
change in miR-122, a liver-specific miR not expressed in the endothelium. This is consistent with a spe-
cific change in the endothelium but deeper analysis of multiple miRs is required. In spot urine samples,
miR-126 was reduced by treatment, which may contribute to the increase in the circulation. miR circulate
encapsulated in extra-cellular vesicles such as exosomes and bound to proteins especially Ago2, but the
relative contribution and biological importance of each fraction is controversial (Chevillet et al., 2014). In
our study, when plasma was fractionated by centrifugation miR-126 predominately remained in the su-
pernatant. This is consistent with studies that report a low amount of miR-126 in human exosomes (Che-
villet et al., 2014). Importantly, we demonstrate here that miR-126 is bound to the circulating protein
Ago2 and this fraction increases in patients with AAV following successful disease treatment. It is re-
ported that stimulation of endothelial cells with TNFa resulted in a decrease of miR-126 (Alexy et al.,
2014). This is in keeping with our own findings and suggests that the reduction in circulating miR-126
in those with active AAV may reflect a degree of endothelial dysfunction secondary to inflammation.
This hypothesis is further supported by miR-126 being enriched in the endothelium (Harris et al., 2008)
and our strong correlation between the circulating miR-126 and markers of endothelial function such
as pulse wave velocity and ADMA. From a clinical perspective, a circulating biomarker that reports
vascular health could have widespread utility and prospective studies should qualify miR-126 in a range
of settings, including other systemic inflammatory disorders such as rheumatoid arthritis and systemic
lupus erythematosus.
In keeping with our hypothesis that miR-126 might act as a measure of vascular integrity, circulating levels
did correlate with well-recognized measures of endothelial dysfunction in our CKD cohort namely, high
PWV, ADMA, ET-1, and urate. Plasma ADMA, an endogenous inhibitor of nitric oxide synthase, and plasma
ET-1 were measured as components of the nitric oxide and ET systems, respectively. Both contribute to
vascular dysfunction in CKD and an imbalance (more ET-1/less nitric oxide) may contribute to vasoconstric-
tion, inflammation and atherosclerosis (Boger, 2003; Dhaun et al., 2006). Serum urate has also emerged as
an important risk factor for cardiovascular risk and CKD progression (Feig et al., 2008). Treatment of asymp-
tomatic hyperuricemia has been shown to improve renal function (Kanbay et al., 2007) and delay disease
progression (Siu et al., 2006) in patients with early CKD. From a clinical perspective, ET receptor antago-
nism is being investigated as a novel therapeutic strategy for renoprotection in CKD (Dhaun and Webb,
2019). It has been shown to not only lower proteinuria but also serum urate (Dhaun et al., 2013; Heerspink
et al., 2019). Furthermore, given there is often reciprocal up-regulation of the nitric oxide system when the
ET system is down-regulated (Dhaun et al., 2006) an ET blocking strategy may offset some of the potentially
deleterious effects of elevated circulating ADMA.
Interestingly, our data suggest no substantial difference in circulating miR-126 between health and CKD.
The lack of a clear differencemay relate to the CKD population we studied as they hadminimal comorbidity
without overt CVD. Additionally, we excluded those with diabetes. Indeed, the ‘‘vascular health’’ of our
CKD subjects is demonstrated by a mean pulse wave velocity of 6.8 m/s, significantly lower than that of
8.2 m/s for a group with a similar eGFR reported in a study by Wang et al. (Wang et al., 2005). They used
a similar technique for measuring arterial stiffness but included patients with diabetes and CVD. Further-
more, our subjects were relatively young (50 years), with good blood pressure control (135/80 mmHg)6 iScience 24, 101937, January 22, 2021
A B
C
Figure 5. Scatterplots of asymmetric dimethylarginine (ADMA)
(A and B) (A) and pulse wave velocity (PWV) (B) versus circulating miR-126 in patients with CKD.




Articleand reasonably preserved renal function (eGFR 75 mL/min). Thus, future studies should extend to the
wider spectrum of CKD.
With further clinical development, miR-126 may have utility as a biomarker of vascular dysfunction in pa-
tients with kidney disease (and possibly in people with normal kidney function). Such a miR biomarker
may provide a readout of cardiovascular drug efficacy that translates from pre-clinical models into early
phase clinical trials. In support of this, we have demonstrated that miR-126 tracks effective treatment in pa-
tients with AAV and reports injury when translated back into a rat model of nephrotoxic nephritis. The work
presented here provides proof of concept data to build on in larger studies that test utility, both in the spe-
cific clinical scenario of reporting disease activity in vasculitis, and across a broader group of patients with
acute kidney injury and CKD.Limitations of the study
miR-126 is expressed in platelets and this represents an alternative source of miR-126 in the circulation.
There was no correlation with the platelet counts across patient groups, but this does not exclude a differ-
ence in platelet activation state. While this cannot be excluded when comparing the AAV patients pre- and
post-treatment it is unlikely to be a factor in the CKD group, where miR-126 correlated significantly with
markers of endothelial dysfunction but not with platelet counts. Future studies could replicate our obser-
vations in platelet poor plasma as described by Sunderland et al. (Sunderland et al., 2017). We represent
miR-126 in AAV as an absolute concentration generated from a standard curve using synthetic miR-126. The
values generated allow comparison across groups, but the absolute value should be interpreted with
caution as the reverse transcription efficiency may differ between synthetic target in buffer and plasma.
Furthermore, release of miR-126 from platelets during sample processing could lead to higher apparent
concentrations than are present in the cell-free fraction in vivo. Our data demonstrate that the Ago2 frac-
tion of miR-126 changes with treatment of patients with AAV. To thoroughly characterize the role of extra-
cellular vesicles, future studies should follow the guidelines published by the International Society of Extra-
cellular Vesicles (Thery et al., 2018).Resource availability
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Supplementary figure 1: Effect of storage on serum & plasma miR-126. Related to figure 2. 
A) Bar graphs displaying median Ct values of miR-126 measured by qPCR. Blood samples 
were collected from healthy volunteers (n=6). One serum and plasma blood tube was 
centrifuged and the supernatant frozen at -80 0C without delay. The remaining blood tubes 
were left at room temperature (RT) or 40C for 24h or 7 days before being processed and stored 
at -80 0C. B) Serum and plasma samples were immediately centrifuged to isolate 
serum/plasma. One serum and one plasma sample were stored at -800C without delay and 
the remaining tubes were left at room temperature (RT) or 40C for 24h or 7 days. Error bars 
represent the interquartile range. 
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Supplementary figure 2: The relationship between plasma miR-126 and platelet count in 
patients with ANCA-associated vasculitis (AAV). Related to figure 2. 
Pre and post treatment (A), chronic kidney disease (B) and End-stage kidney disease (C).  




















Pre-treatment  Pearson r (95%CI) -0.07 (-0.33 to 0.20) P=0.6
Post-treatment Pearson r (95%CI) 0.09 (-0.19 to 0.36) P=0.5


















Pearson r (95%CI) 0.24 (-0.53 to 0.49) P=0.2



















Pearson r (95%CI) -0.02 (-0.53 to 0.49) P=0.9
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Supplementary figure 3: Standard curves used for absolute quantification of miRs. Related 
to Figure 2. 
(A) miR-122 and (B) miR-126 standard curves for absolute quantification in patient samples. 





Participant groups  
All studies were approved by the local research ethics committee and performed in 
accordance with the Declaration of Helsinki. The study, entitled “MicroRNA signatures of 
disease activity in ANCA-associated vasculitis”, REC reference 13/ES/0126 (formerly 
10/S1402/33) was approved by The Tissue Governance committee in June 2015. Informed 
consent was obtained from all study participants.  
 
Patients with ANCA Associated Vasculitis (AAV) 
Patients presenting with AAV were recruited at the Royal Infirmary of Edinburgh, UK. Inclusion 
criteria were seropositivity for ANCA and organ-threatening disease requiring 
immunosuppression. Disease activity was graded according to the BVAS (scores range from 
0 to 63, with higher scores indicating more active disease) (Mukhtyar et al., 2009) and by 
investigators’ assessments of disease activity as remission, ongoing active disease (treatment 
failure), or relapse. Remission was defined as a BVAS score of 0 that was maintained for 2 
months and a prednisone dosage of ≤10 mg/day.  
 
Patients with CKD  
Subjects were recruited from the renal outpatient clinic at the Royal Infirmary of Edinburgh. 
The inclusion criteria were: male or female CKD patients, 18-65 years old and clinic BP 
≤160/100 mmHg, whether or not on anti-hypertensive medication. We excluded patients with 
a renal transplant or on dialysis, patients with systemic vasculitis or connective tissue disease, 
those with a history of established cardiovascular disease, peripheral vascular disease, 




Patients with ESRD 
Inclusion criteria were: age 18 or over, treated with haemodialysis (HD) for over 3 months. 
Patients affected by liver disease or with a history of hepato-biliary surgery were excluded; 
other exclusion criteria were consumption of cytochrome P450-inducing medications, past 
medical history of epilepsy, cancer, alcoholism and/or psychiatric disease. All patients were 
treated with HD for 4-5 hours per session, 3 times per week. Data collected included 
demographic characteristics, cause of ESRD, time on dialysis and current medications. As 
heparin in blood samples can inhibit polymerase chain reaction (PCR), blood samples were 
only used when the patient had not been exposed to heparin in the preceding 24 hours. 
 
Healthy subjects 
Adults with no medical complaints and no medication use were recruited and blood was drawn 
with informed consent.  
 
Blood samples 
In healthy subjects, blood was collected into 3 EDTA plasma (2.7 ml) and 3 serum (4.9 ml) 
tubes. One of each type of blood tube was processed without delay – by centrifugation at 1200 
x g for 10 min at 40C and then supernatant then frozen at -800C. The remaining tubes of blood 
were left unprocessed at room temperature or 40C for 24h or 7 days. Hemolysis was quantified 
by spectrophotometric methods as described previously (Kirschner et al., 2013). In a second 
study plasma and serum was left at room temperature or 40C for 24h or 7 days.  
 
In patients with AAV, blood samples were taken at study entry (before treatment) and at 
disease remission (as defined above). For CKD patients, samples were taken from a 
previously published study and were collected on the study day (Lilitkarntakul et al., 2011). 
Blood was collected into EDTA tubes and processed immediately as above. Urine was also 
collected and immediately frozen at -800C.  
 
Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide 
synthesis, was measured using an optimised, fully validated high performance liquid 
chromatography method (intra- and inter-assay variations of 1.9% and 2.3%, respectively) 
(Blackwell et al., 2007). Plasma endothelin-1 (ET-1), the most potent endogenous 
vasoconstrictor, which contributes to CKD development and progression,(Dhaun et al., 2006) 
was determined by radioimmunoassay (Peninsular Laboratories Europe, St. Helens, UK) 
(assay variations 6.3% and 7.2%) (Strachan et al., 1999). The urate assay was based on the 
methods of Trivedi and Kabasakalian (Trivedi et al., 1978). Uric acid is oxidized to allantoin by 
uricase with the production of hydrogen peroxide (H2O2). The H2O2 reacts with 4-
aminoantipyrine (4-AAP) and 2,4,6-tribromo-3-hydroxybenzoic acid (TBHB) in the presence 
of peroxidase to yield a quinoneimine dye. The resulting change in absorbance at 548 nm is 
proportional to the uric acid concentration in the sample. The limits of detection and 
quantification for the urate assay are 0.01 mmol/l and 0.015 mmol/l, respectively. 
 
Extra-cellular vesicle isolation 
Human plasma was fractionated by differential centrifugation to concentrate extra-cellular 
vesicles, as previously described (Chevillet et al., 2014). Plasma (1 mL) was centrifuged at 
500 x g for 30 min then 12,000 x g for 20 min. The supernatant was then ultracentrifuged at 
100,000 x g for 1h to pellet extra-cellular vesicles. The remaining supernatant is referred to as 
the ‘protein fraction’. The vesicles were re-suspended and then pelleted a second time by 
ultracentrifugation. Extra-cellular vesicle presence and number was quantified by nanoparticle 
tracking analysis as previously described (Oosthuyzen et al., 2013). miR concentration in each 
fraction was determined by PCR, described below. 
 
Ago2 isolation 
MagnaBind goat anti-mouse IgG magnetic bead slurry, 100 μL, (Thermo Scientific, Waltham, 
USA) was incubated with 10 μg of mouse monoclonal anti-Ago2 (Abcam, Cambridge, UK) or 
mouse normal IgG (Santa Cruz Biotechnology, Dallas, US) antibodies for 2h at 4°C. The 
antibody-coated beads were then added to plasma and incubated overnight at 4°C with 
rotation. Beads were washed and each sample then eluted in RNAse free water before QIAzol 
was added for RNA isolation. Ago2 isolation was determined by Western blot analysis as 
described (Dear et al., 2011). 
 
Measurement of arterial stiffness 
In a subset of patients gold standard pulse wave velocity (PWV) was measured by the foot-
to-foot wave velocity method using the SphygmoCorTM system (SphygmoCorTM Mx, AtCor 
Medical, Sydney, Australia, version 6.31), in which a high-fidelity micromanometer (SPC-301, 
Millar Instruments, Texas, USA) was used to determine carotid-femoral PWV (Oliver and 
Webb, 2003). 
 
Measurement of plasma and urine miR 
The following miR were measured: miR-126-3p, miR-122-5p, miR-1287 and miR-671. 
 
RNA extraction 
RNA was extracted from each sample (50 µl) using the miRNeasy serum/plasma kit (Qiagen, 
Venlo, Netherlands).  
  
PCR 
After RNA extraction, 5 µl of each eluate was reverse transcribed into cDNA using the miScript 
II RT Kit (Qiagen, Venlo, Netherlands). The synthesised cDNA was ten-fold diluted and used 
for cDNA template in combination with the miScript SYBR Green PCR Kit (Qiagen, Venlo, 
Netherlands) using the specific miScript assays (Qiagen, Venlo, Netherlands). Real-time PCR 
was performed on a Light Cycler 480 (Roche, Basel, Switzerland) using the recommended 




Absolute miRNA quantification 
Absolute quantification of miRs was achieved by generating a standard curve using synthetic 
target. Standard curves were generated by reverse transcribing known concentrations of 
miScript miRNA mimics (Qiagen, Venlo, The Netherlands) in 0.1X TE buffer spiked with 10 
ng/μl Poly-C (Sigma-Aldrich, Gillingham, UK). The resulting cDNA was measured using serial 
dilutions on 3 different plates on three different days to demonstrate minimal variability 
(Supplementary Figure 3). 
 
Relative quantification 
MiR expression was analysed using the DCt method (Schmittgen and Livak, 2008). A C. 
elegans miR mimic was used as a spiked-in control (miR-39). This allowed for the Ct values 
for the miRs of interest to be normalised to the spiked-in control. The data obtained were 
translated by the 2-DCt method. 
 
Statistical analysis 
Data are presented as mean ± standard deviation for patient characteristics and as median 
and interquartile range (IQR) for all other datasets. Each dataset was analysed for normality 
using a Shapiro-Wilk test. For non-parametric datasets, comparisons were made using the 
Mann-Whitney test or Wilcoxon matched-pairs signed rank test. For the study of patients with 
ANCA vasculitis, with 70 patients the probability is 80% that the study will detect a pre- and 
post-treatment difference in miR-126 of 65 at a two-sided 0.05 significance level. This is based 
our pilot data that demonstrated a standard deviation of the change in miR-126 pre- and post-
treatment of 190. In our pilot data the mean change in miR-126 was 125 and a change of 65 




Rat model of nephrotoxic nephritis (NTN) 
NTN was induced by raising a nephrotoxic serum (NTS) in rabbits to isolated sonicated rat 
glomeruli which was then injected into male Sprague-Dawley rats (1mL/200 g). A telescoped 
model of NTN was used where the rats are pre-immunised with 1 mg rabbit immunoglobulin 
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